Kanwaldeep Kaur Mallhi, MD

Kanwaldeep Kaur Mallhi, MD

Cancer and Blood Disorders Center, Non-Malignant Transplant Program, Pediatric Blood and Marrow Transplant Program

On staff since October 2016

Children's Title: Attending Physician, Cancer and Blood Disorders Center

Academic Title: Assistant Professor, Department of Pediatrics, University of Washington School of Medicine

"Seeing patients cured — or doing so well that they don’t even remember how badly they once felt — is a big reward of this job."

  • Dr. Kanwaldeep Mallhi is a pediatric oncologist and hematologist who specializes in nonmalignant blood disorders in children. 

     

     

    These disorders include immunodeficiencies, bone marrow failure and metabolic errors. She is an expert in pediatric blood stem cell transplants, and her research focuses on alternative donor sources and the development of reduced-intensity conditioning regimens, which use radiation, chemotherapy or other procedures to remove diseased or failing cells prior to transplant. 

    Dr. Mallhi also is an assistant professor in the Department of Pediatrics at the University of Washington School of Medicine and an assistant professor in the Clinical Research Division at Fred Hutchinson Cancer Center. 

     

     

    • Related Pages

    • Kanwaldeep Mallhi, M.D.

      Faculty profile for Dr. Kanwaldeep Mallhi. Dr. Mallhi is a pediatric oncologist and hematologist who specializes in nonmalignant blood disorders in children.

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

Rosalind Franklin University of Medicine/Science, North Chicago, IL

Fellowship

University of Minnesota at Minneapolis, Minneapolis, MN

Clinical Interests

Active Clinical Trials:

Study Number 2032: Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Study Number 9818:  Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Study Number 9867:  Haploidentical Bone Marrow Transplantation in Sickle Cell Patients

 

Research Description

My research is focused on develop local and national expertise in HCT for non-malignant disorders. Specific areas of interest include inborn errors of metabolism disorders and bone marrow failure syndromes, utilizing reduced intensity conditioning regimens, alternative donors and gene editing.